Tatem describes tendon-healing findings from rat models and says no major negative effects have been seen in human patients so far. Crucially, he also states that animal findings do not translate one-to-one to humans and that more data are needed, so the episode does not establish human efficacy or long-term safety.

The cited tendon evidence comes from animal models
Tatem says human experience has not shown obvious severe effects in his practice
He explicitly rejects a one-to-one animal-to-human translation
The episode calls for more data

“If you have an Achilles tendon injury and you're a rat, BPC 157 is one of the best things that you can ever have.”
Dr. Alex Tatem · 08:00

“That is not a one-to-one translation to what we might see in humans”
Dr. Alex Tatem · 08:00

#bpc-157#animal studies#evidence quality

Myth Buster36:30

Peptides Do Not Replace the Training Stimulus for Muscle

Tatem pushes back on social-media claims that peptides independently add substantial lean mass. He says IGF-1 LR3 may influence muscle at higher doses, but meaningful muscle gain still requires training, while peptide or hormone use brings separate risks and does not replace nutrition or coaching.

Tatem calls muscle-building claims a common social-media misnomer
He says significant lean-mass gain still requires gym stimulus
Medical treatment does not replace a trainer or nutrition support
Higher-dose growth-related compounds can carry meaningful risks

“One of the things that peptides can't do for you is independently put on significant amounts of lean mass.”
Dr. Alex Tatem · 37:30

#muscle#training#igf-1

Myth Buster56:00

Growth-Hormone Peptides Are Not a Harmless Anti-Aging Shortcut

Tatem describes CJC-1295 and ipamorelin as secretagogues intended to stimulate endogenous growth-hormone release through different mechanisms. He then lists serious risks associated with excessive or prolonged growth-hormone exposure, including insulin resistance, irreversible acromegalic bone changes, joint-fluid effects, and a theoretical concern about worsening an existing cancer.

CJC-1295 and ipamorelin are described as acting through different pathways
Claimed benefits include recovery, body composition, and skin changes
Excess exposure may worsen glucose control
Tatem warns of irreversible bone changes with abuse
He distinguishes a theoretical existing-cancer concern from causing new cancer

“If you take a little bit too much, you can actually get insulin resistance because your glucose levels will go too high for too long”
Dr. Alex Tatem · 58:00

“We've never shown it that it causes new cancers, but that could be a concern.”
Dr. Alex Tatem · 58:30

#growth hormone#cjc-1295#ipamorelin#risk

Myth Buster59:00

Why Tatem Is Skeptical of Epithalon as a Fountain of Youth

Tatem explains the hypothesis that epithalon may encourage telomerase activity, while noting that shorter telomeres are associated with ageing. He explicitly rejects overconfidence in the ‘fountain of youth’ framing and instead points to possible circadian-related effects. The episode supplies no human longevity outcome data.

The proposed mechanism involves telomerase and telomeres
An association between shorter telomeres and ageing does not prove lifespan extension
Tatem is openly skeptical of anti-ageing hype
No human longevity results are presented

“I'm very skeptical as far as that goes”
Dr. Alex Tatem · 1:00:30

#epithalon#telomeres#longevity

Hot Take· 2

Hot Take30:00

The Case Tatem Makes for Customized Compounded GLP-1s

Tatem argues that a compounded tirzepatide formulation can permit more flexible clinician-directed dosing than a standardized weekly pen and may help some patients who feel unwell after a larger single dose. These are his clinical claims and policy views; the transcript does not provide comparative trial evidence establishing that split dosing is safer or better.

Commercial pens deliver standardized approved regimens
Compounded formulations can allow customized dosing
Tatem says some patients tolerate divided doses better
He calls for patient choice under medical supervision
No comparative efficacy or safety data are presented

“What you want is you want an ecosystem where you have choice so you can make the right choice for the right patient.”
Dr. Alex Tatem · 33:30

#glp-1#compounding#personalized medicine

Hot Take1:08:30

Tatem's Case That Metabolic Disease Is a Major Fertility Risk

Tatem says multiple studies show declining male sperm concentration, motility, and quality over time. He names environmental toxins and microplastics as suspected contributors but emphasizes insulin resistance, obesity, and metabolic disease as modifiable risks. His broader claims connecting metabolic dysfunction to many diseases are sweeping and are not fully evidenced within this transcript.

Tatem says the fertility decline persists under increased scrutiny
Environmental exposures are presented as possible contributors
He identifies metabolic dysfunction as a major modifiable factor
He speculates that earlier metabolic treatment could prevent some specialist referrals
The episode does not quantify each factor's causal contribution

“The biggest modifiable risk factor is insulin resistance and metabolic disease.”
Dr. Alex Tatem · 1:09:30

#male fertility#obesity#insulin resistance

Explainer· 6

Explainer03:30

What Peptides Are—and Why ‘Targeted’ Does Not Mean Risk-Free

Tatem describes peptides as short amino-acid chains that can act on particular receptors or cellular pathways. He contrasts their targeted action with the broader effects of many small-molecule drugs, while the rest of the conversation makes clear that targeted action does not remove side effects or evidence gaps.

Peptides are assembled from amino acids
Their structure can target particular receptors or pathways
Insulin is cited as an early medical peptide
Target specificity is not the same as guaranteed safety

“These are fragments of proteins that are designed to specifically target certain receptors and affect cells in a very targeted fashion.”
Dr. Alex Tatem · 04:00

#peptides#amino acids#receptors

Explainer09:30

The Patent and Compounding Story Behind the Peptide Boom

Tatem links current peptide access to two regulatory threads: limits on patenting naturally occurring material and tighter federal oversight after a serious compounding-pharmacy contamination event. He argues that weak commercial incentives can leave promising unpatentable compounds underfunded, but his suggestions of pharmaceutical influence over later restrictions remain allegations and suspicions rather than demonstrated fact in the transcript.

Tatem cites the 2013 Myriad Genetics decision on naturally occurring genes
He describes federal compounding oversight following a fungal-meningitis outbreak
He says 19 popular compounds were moved to a prohibited category in 2023
The episode does not provide proof for claims that pharmaceutical pressure caused the move

“I try to walk a very fine line between what I can prove versus what I suspect after being in this space for a long…”
Dr. Alex Tatem · 18:30

#regulation#compounding#patents#fda

Explainer39:00

GHK-Cu Skin Claims: Plausible Mechanism, Limited Detail

Tatem identifies topical GHK-Cu as a copper tripeptide used in skin products and says it may support collagen, elastin, and visible skin quality. He distinguishes topical availability from injectable regulation and is more cautious about hair benefits. The transcript offers no study details, effect sizes, or long-term safety data, so these remain his clinical interpretation rather than a complete evidence review.

GHK-Cu is described as a copper tripeptide
Tatem says topical use may improve visible skin quality
He does not present it as a replacement for cosmetic procedures
He characterizes reported hair benefits as less consistent

“The those reports are a little bit more spotty.”
Dr. Alex Tatem · 1:08:00

#ghk-cu#skin#collagen

Explainer41:00

What Tatem Claims Semax, DSIP, and Selank May Do

Tatem discusses intranasal Semax in connection with recovery after brain injury or stroke and possible cognitive effects, then describes DSIP and Selank as potentially relevant to circadian rhythm or sleep. He avoids directly prescribing them and repeatedly frames legal access and future evidence as unresolved. No trial design, effect size, or safety profile is supplied in the episode.

Semax is discussed as an intranasal peptide studied after neurological injury
DSIP is linked by Tatem to circadian regulation
Selank is described as potentially calming before sleep
The conversation does not establish broad cognitive enhancement
Tatem does not recommend listeners self-administer these products

“I wouldn't say necessarily recommend, but I would say if we're looking at how these medications have been used”
Dr. Alex Tatem · 41:00

#semax#sleep#cognition#dsip

Explainer54:00

Retatrutide Adds a Third Receptor—and Much Bigger Claims

Tatem explains retatrutide as a GLP-1, GIP, and glucagon-receptor agonist, contrasting it with single- and dual-agonist medicines. He says clinical trials and anecdotal users have shown unusually large weight loss and liver-health improvements, but the transcript provides no study citation and also notes that unsupervised research-market use preceded commercialization.

Retatrutide is described as a triple-receptor agonist
Glucagon activation is linked to mobilizing stored liver energy
Tatem reports strong weight-loss and liver-health findings
He predicts blockbuster commercial impact
Research-market use is not evidence of safety or approval

“It's not for everybody, right? It's going to go faster than everything else, but it's going to change the game.”
Dr. Alex Tatem · 1:03:30

#retatrutide#glp-1#liver health

Explainer1:22:30

How an Inflatable Penile Implant Restores Mechanical Function

Tatem explains that severe vascular erectile dysfunction may stop responding to oral medicines, while injections can be unappealing to some patients. He describes an internal implant with cylinders, a concealed fluid reservoir, and a pump in the scrotum that mechanically creates and releases rigidity while avoiding the sensory nerves. His procedure-time and satisfaction claims reflect his practice and are not independently substantiated in the transcript.

Long-term vascular disease can impair penile blood flow
The implant places inflatable cylinders inside the natural erectile bodies
A concealed pump transfers saline from an internal reservoir
Tatem says the operation avoids the nerves responsible for sensation
He presents implants as an option after simpler treatments fail

“It does not affect sensation. And so the nerves that affect sensation run along the top of the penis.”
Dr. Alex Tatem · 1:25:00

#erectile dysfunction#penile implant#urology

Story· 2

Story21:30

A Reported Tenfold Sperm-Count Rise After Major Weight Loss

Tatem recounts one patient with obesity, insulin resistance, low testosterone signalling, and a low sperm count. He says the patient lost 100 pounds using tirzepatide alongside exercise and dietary changes, after which the sperm count rose tenfold into a normal range. This is a clinician's anecdote with multiple simultaneous interventions, not evidence that tirzepatide alone caused the result.

Tatem frames metabolic dysfunction as a possible upstream contributor
The patient used medication, exercise, and dietary improvement together
The reported sperm-count change was tenfold
A single multi-intervention case cannot establish causation

“I just saw a patient last last week who increased his sperm count 10 times over and is now in a normal range”
Dr. Alex Tatem · 22:30

#fertility#metabolic health#tirzepatide

Story1:12:00

The Surgical Crisis That Changed How Tatem Cared for Himself

Tatem recounts working 80-to-100-hour weeks during medical training, then facing a postoperative bleed after a difficult kidney operation. Although the patient recovered, Tatem says the event left him devastated and contributed to a decision to prioritize his own health alongside patient care. He connects that experience and his family's fertility struggle to his strong identification with men's-health patients.

Tatem describes grueling training and prolonged self-neglect
A difficult postoperative emergency became an emotional breaking point
The patient ultimately recovered
Tatem sought evaluation and recommitted to his health
Personal fertility experience informs his clinical empathy

“I made a commitment to take care of my patients, to take care of myself, and make that a priority”
Dr. Alex Tatem · 1:15:30

“These are our brothers and this is who I have been called to care for.”
Dr. Alex Tatem · 1:17:30

#burnout#surgery#patient care#recovery

Takeaway· 1

Takeaway26:30

Why ‘Research Use Only’ Peptides Are a Quality-Control Gamble

Tatem says the 2023 restrictions pushed consumer demand toward sellers labelling compounds for research use only. He warns that these products may lack dependable identity, purity, dosing, and contamination controls, and explicitly advises listeners not to buy them for personal use.

A research label does not make a product appropriate for injection
Identity and dose may be uncertain
Contamination and endotoxin removal may be unclear
Tatem prefers legal prescribing through regulated pharmacies

“You don't really know if it's sushi and it may not end very well for you.”
Dr. Alex Tatem · 27:30

“Don't go out and buy research use only compounds.”
Dr. Alex Tatem · 1:01:30

#grey market#quality control#safety

Frameworks in this episode

Problem-First Treatment Toolbox

Upside-Trade-off Check

Weight-Loss Maintenance Bridge

Insights & moments

⚡Myth Buster· 4

BPC-157: Striking Animal Results Are Not Human Proof